Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases

Current Opinion in Pediatrics

Volumn 25, Issue 2, 2013, Pages 225-231

  Nester, Carla M ^a,b   Brophy, Patrick D ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antibody mediated rejection; Atypical haemolytic uraemic syndrome; C3 glomerulopathy; Complement; Eculizumab; Membranoproliferative glomerulonephritis; Shiga toxin associated haemolytic uraemic syndrome

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; NEPHRITIC FACTOR;

ANTIBODY MEDIATED REJECTION; CLINICAL TRIAL (TOPIC); COMPLEMENT MEDIATED RENAL DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE COMPLEX DEPOSITION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SHIGA TOXIN ASSOCIATED HEMOLYTIC UREMIC SYNDROME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; GLOMERULONEPHRITIS; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84875324495     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32835df4a3     Document Type: Review

References (50)

1. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552-559.
2. Appel G, Nachman P, Hogan S, et al. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2002; 13:A668.
3. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002; 3:1017-1023.
4. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360:544-546.
5. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolyticuremic syndrome. N Engl J Med 2009; 360:542-544.
6. Maga TK, Nishimura CJ, Weaver AE, et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31:E1445-E1460.
7. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844-1859.
8. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: The impact of MCP CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108:1267-1279.
9. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008; 23:1957-1972.
10. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: Genetics and disease associations of human complement factor H. Clin Exp Immunol 2008; 151:1-13.
11. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53:836-844.
12. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: Update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007; 28:222-234.
13. Roumenina LT, Jablonski M, Hue C, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114:2837-2845.
14. Tawadrous H, Maga T, Sharma J, et al. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol 2010; 25:947-951.
15. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112:4948-4952.
16. Lhotta K, Janecke AR, Scheiring J, et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009; 4:1356-1362.
17. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41:e84.
18. Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:2150-2155.
19. Kavanagh D, Richards A, Noris M, et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008; 45:95-105.
20. Nilsson SC, Kalchishkova N, Trouw LA, et al. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 2010; 40:172-185.
21. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100:12966-12971.
22. Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362:1542-1547.
23. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic uremic syndrome. N Engl J Med 2009; 361:345-357.
24. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3:e41.
25. Dragon-Durey MA, Blanc C, Marliot F, et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46:447-450.
26. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115:379-387.
27. Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111:1512-1514.
28. Fakhouri F, Fremeaux-Bacchi V, Noel L-H, et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol 2010; 6:494-499.
29. Servais A, Fremeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193-199.
30. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 2005; 16:1392-1403.
31. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20:605-616.
32. Levy M, Halbwachs-Mecarelli L, Gubler M-C, et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30:949-956.
33. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15:787-795.
34. Licht C, Heinen S, Jozsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70:42-50.
35. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120:3702-3712.
36. Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: Clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6:1436-1446.
37. Vernon KA, Goicoechea de Jorge E, Hall AE, et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 2012; 60:121-125.
38. Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454-464.
39. Pickering MC, Warren J, Rose KL, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A 2006; 103:9649-9654.
40. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366:1163-1165.
41. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366:1161-1163.
42. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am J Transplant 2012; 12:1046-1051.
43. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748-756.
44. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561-2563.
45. Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: An analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27:3807-3815.
46. Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study. BMJ 2012; 345:e4565.
47. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464-470.
48. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8:2684-2694.
49. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
50. Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366:1165-1166.